| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 114 | 2024 | 346 | 23.140 |
Why?
|
| Pulmonary Artery | 69 | 2024 | 306 | 6.760 |
Why?
|
| Mitochondrial Dynamics | 20 | 2024 | 53 | 6.180 |
Why?
|
| Muscle, Smooth, Vascular | 45 | 2019 | 231 | 5.870 |
Why?
|
| Vasoconstriction | 51 | 2021 | 93 | 5.780 |
Why?
|
| Oxygen | 47 | 2023 | 726 | 5.170 |
Why?
|
| Ventricular Dysfunction, Right | 18 | 2023 | 134 | 4.860 |
Why?
|
| Mitochondrial Proteins | 13 | 2022 | 123 | 4.410 |
Why?
|
| Mitochondria | 27 | 2022 | 535 | 4.340 |
Why?
|
| Ductus Arteriosus | 16 | 2023 | 26 | 4.270 |
Why?
|
| Potassium Channels | 41 | 2015 | 340 | 4.220 |
Why?
|
| Hypoxia | 50 | 2022 | 641 | 3.820 |
Why?
|
| Pulmonary Circulation | 30 | 2023 | 86 | 3.800 |
Why?
|
| Ventricular Function, Right | 15 | 2023 | 142 | 3.750 |
Why?
|
| Dynamins | 12 | 2024 | 49 | 3.560 |
Why?
|
| Rats | 94 | 2023 | 3990 | 3.060 |
Why?
|
| Hypertrophy, Right Ventricular | 14 | 2023 | 33 | 3.050 |
Why?
|
| Nitric Oxide | 30 | 2015 | 278 | 3.010 |
Why?
|
| Heart Ventricles | 14 | 2022 | 760 | 2.700 |
Why?
|
| GTP Phosphohydrolases | 9 | 2023 | 71 | 2.670 |
Why?
|
| Disease Models, Animal | 27 | 2023 | 2232 | 2.590 |
Why?
|
| Lung | 41 | 2024 | 1170 | 2.520 |
Why?
|
| Myocytes, Smooth Muscle | 14 | 2021 | 132 | 2.520 |
Why?
|
| Animals | 164 | 2024 | 26582 | 2.440 |
Why?
|
| Rats, Sprague-Dawley | 51 | 2022 | 1219 | 2.400 |
Why?
|
| Epigenesis, Genetic | 8 | 2020 | 479 | 2.340 |
Why?
|
| Potassium Channels, Voltage-Gated | 14 | 2011 | 122 | 2.310 |
Why?
|
| Mitochondrial Diseases | 4 | 2016 | 10 | 2.080 |
Why?
|
| Oxidation-Reduction | 32 | 2022 | 373 | 2.060 |
Why?
|
| Reactive Oxygen Species | 18 | 2024 | 480 | 2.030 |
Why?
|
| Cardiovascular Diseases | 9 | 2023 | 827 | 1.990 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2024 | 57 | 1.950 |
Why?
|
| Vasodilator Agents | 11 | 2019 | 152 | 1.930 |
Why?
|
| Humans | 184 | 2024 | 86643 | 1.870 |
Why?
|
| Heart Failure | 14 | 2023 | 1204 | 1.780 |
Why?
|
| Microtubule-Associated Proteins | 7 | 2018 | 176 | 1.720 |
Why?
|
| Mitochondria, Muscle | 5 | 2015 | 26 | 1.710 |
Why?
|
| Antihypertensive Agents | 11 | 2021 | 521 | 1.700 |
Why?
|
| Pulmonary Wedge Pressure | 7 | 2021 | 108 | 1.660 |
Why?
|
| Vasodilation | 15 | 2014 | 96 | 1.540 |
Why?
|
| Oxygen Consumption | 8 | 2016 | 239 | 1.540 |
Why?
|
| Peptide Elongation Factors | 4 | 2022 | 28 | 1.530 |
Why?
|
| Piperazines | 11 | 2011 | 272 | 1.480 |
Why?
|
| Hemodynamics | 22 | 2020 | 710 | 1.470 |
Why?
|
| Neoplasms | 9 | 2023 | 2898 | 1.470 |
Why?
|
| Mitochondria, Heart | 5 | 2024 | 50 | 1.450 |
Why?
|
| Signal Transduction | 16 | 2020 | 3241 | 1.430 |
Why?
|
| Ductus Arteriosus, Patent | 6 | 2023 | 38 | 1.370 |
Why?
|
| Phosphodiesterase Inhibitors | 10 | 2009 | 30 | 1.360 |
Why?
|
| Cardiology | 5 | 2021 | 123 | 1.270 |
Why?
|
| Vascular Resistance | 19 | 2019 | 102 | 1.240 |
Why?
|
| Cell Proliferation | 10 | 2021 | 1578 | 1.240 |
Why?
|
| Male | 110 | 2022 | 40965 | 1.230 |
Why?
|
| Pulmonary Embolism | 4 | 2023 | 222 | 1.200 |
Why?
|
| Superoxide Dismutase | 9 | 2016 | 177 | 1.190 |
Why?
|
| Cell Cycle | 3 | 2023 | 502 | 1.190 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 3 | 2019 | 9 | 1.140 |
Why?
|
| Hydrogen Peroxide | 15 | 2021 | 158 | 1.130 |
Why?
|
| Calcium Channels | 10 | 2017 | 182 | 1.080 |
Why?
|
| Cardiac Catheterization | 5 | 2020 | 291 | 1.040 |
Why?
|
| Calcium | 17 | 2024 | 1156 | 1.040 |
Why?
|
| Cells, Cultured | 21 | 2020 | 2818 | 1.030 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 1.030 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 1.020 |
Why?
|
| Enzyme Inhibitors | 9 | 2019 | 639 | 1.010 |
Why?
|
| Genetic Therapy | 9 | 2017 | 342 | 0.970 |
Why?
|
| Myocytes, Cardiac | 8 | 2024 | 275 | 0.960 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 7 | 2020 | 151 | 0.950 |
Why?
|
| Receptors, Adrenergic, beta | 2 | 2014 | 72 | 0.910 |
Why?
|
| Potassium Channel Blockers | 12 | 2005 | 64 | 0.900 |
Why?
|
| Apoptosis | 11 | 2020 | 1683 | 0.880 |
Why?
|
| Sulfones | 10 | 2011 | 43 | 0.880 |
Why?
|
| Dichloroacetic Acid | 6 | 2012 | 11 | 0.880 |
Why?
|
| Vascular Diseases | 1 | 2023 | 121 | 0.880 |
Why?
|
| Lipoma | 1 | 2022 | 25 | 0.860 |
Why?
|
| Adaptation, Physiological | 3 | 2015 | 306 | 0.860 |
Why?
|
| Pulmonary Veins | 7 | 2018 | 72 | 0.850 |
Why?
|
| Female | 70 | 2022 | 44532 | 0.840 |
Why?
|
| Epoprostenol | 7 | 2012 | 46 | 0.820 |
Why?
|
| Heart Defects, Congenital | 3 | 2023 | 351 | 0.780 |
Why?
|
| Lung Neoplasms | 5 | 2022 | 2262 | 0.780 |
Why?
|
| Cyclic GMP | 9 | 2014 | 58 | 0.770 |
Why?
|
| Carotid Body | 2 | 2022 | 234 | 0.760 |
Why?
|
| Fatty Acids | 5 | 2015 | 130 | 0.760 |
Why?
|
| Altitude Sickness | 1 | 2020 | 10 | 0.750 |
Why?
|
| In Vitro Techniques | 28 | 2005 | 989 | 0.750 |
Why?
|
| Endothelium, Vascular | 14 | 2020 | 435 | 0.740 |
Why?
|
| Quinazolinones | 3 | 2015 | 13 | 0.740 |
Why?
|
| Neutrophils | 1 | 2021 | 307 | 0.740 |
Why?
|
| Stroke Volume | 3 | 2021 | 456 | 0.740 |
Why?
|
| Patch-Clamp Techniques | 21 | 2008 | 396 | 0.730 |
Why?
|
| Mice | 23 | 2024 | 11352 | 0.730 |
Why?
|
| Monocrotaline | 10 | 2022 | 12 | 0.730 |
Why?
|
| Glycolysis | 6 | 2017 | 129 | 0.720 |
Why?
|
| House Calls | 1 | 2019 | 9 | 0.720 |
Why?
|
| Videoconferencing | 1 | 2019 | 16 | 0.720 |
Why?
|
| Pressure | 1 | 2020 | 165 | 0.710 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 138 | 0.710 |
Why?
|
| Myofibroblasts | 1 | 2020 | 43 | 0.710 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 239 | 0.700 |
Why?
|
| Ventricular Dysfunction | 1 | 2019 | 28 | 0.690 |
Why?
|
| Pyrazoles | 3 | 2018 | 153 | 0.690 |
Why?
|
| Blood Pressure | 17 | 2020 | 1143 | 0.690 |
Why?
|
| Pyrimidines | 4 | 2018 | 370 | 0.670 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 263 | 0.670 |
Why?
|
| Familial Primary Pulmonary Hypertension | 7 | 2023 | 60 | 0.670 |
Why?
|
| Colchicine | 2 | 2020 | 23 | 0.660 |
Why?
|
| Health Policy | 1 | 2020 | 180 | 0.660 |
Why?
|
| Biomedical Research | 2 | 2021 | 376 | 0.650 |
Why?
|
| Health Equity | 1 | 2020 | 77 | 0.650 |
Why?
|
| Metabolic Syndrome | 2 | 2019 | 141 | 0.650 |
Why?
|
| Ambulatory Care | 1 | 2019 | 181 | 0.640 |
Why?
|
| Microtubules | 2 | 2021 | 119 | 0.630 |
Why?
|
| Patient Care Management | 1 | 2017 | 31 | 0.620 |
Why?
|
| Tubulin Modulators | 1 | 2017 | 24 | 0.610 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 79 | 0.600 |
Why?
|
| Models, Biological | 9 | 2013 | 1749 | 0.600 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2017 | 10 | 0.600 |
Why?
|
| Membrane Potentials | 19 | 2010 | 435 | 0.600 |
Why?
|
| Middle Aged | 40 | 2021 | 25028 | 0.600 |
Why?
|
| Kv1.5 Potassium Channel | 8 | 2007 | 12 | 0.590 |
Why?
|
| Potassium Channels, Calcium-Activated | 4 | 2004 | 19 | 0.590 |
Why?
|
| Telemedicine | 1 | 2019 | 169 | 0.580 |
Why?
|
| Membrane Proteins | 3 | 2021 | 1196 | 0.580 |
Why?
|
| Echocardiography | 9 | 2020 | 911 | 0.580 |
Why?
|
| Cation Transport Proteins | 1 | 2017 | 64 | 0.570 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 115 | 0.570 |
Why?
|
| 4-Aminopyridine | 10 | 2004 | 32 | 0.560 |
Why?
|
| MicroRNAs | 3 | 2018 | 534 | 0.550 |
Why?
|
| Guanylate Cyclase | 2 | 2014 | 18 | 0.550 |
Why?
|
| STAT2 Transcription Factor | 1 | 2015 | 6 | 0.550 |
Why?
|
| Heart Arrest | 2 | 2020 | 265 | 0.550 |
Why?
|
| Sildenafil Citrate | 10 | 2011 | 22 | 0.540 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 426 | 0.530 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 4 | 2020 | 14 | 0.530 |
Why?
|
| Glucose | 3 | 2013 | 638 | 0.530 |
Why?
|
| Purines | 10 | 2011 | 91 | 0.520 |
Why?
|
| Long QT Syndrome | 2 | 2012 | 34 | 0.520 |
Why?
|
| Rabbits | 11 | 2023 | 636 | 0.520 |
Why?
|
| Transcriptome | 2 | 2021 | 580 | 0.520 |
Why?
|
| Luminescent Measurements | 11 | 2001 | 57 | 0.500 |
Why?
|
| Infant, Newborn | 12 | 2023 | 2379 | 0.500 |
Why?
|
| Nutritional Sciences | 2 | 2004 | 12 | 0.490 |
Why?
|
| Drug Design | 1 | 2014 | 124 | 0.490 |
Why?
|
| Electrocardiography | 4 | 2013 | 478 | 0.490 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 122 | 0.480 |
Why?
|
| Macrophages | 3 | 2022 | 554 | 0.480 |
Why?
|
| Cell Hypoxia | 8 | 2005 | 164 | 0.480 |
Why?
|
| Dyspnea | 3 | 2022 | 73 | 0.470 |
Why?
|
| Chronic Disease | 11 | 2023 | 971 | 0.470 |
Why?
|
| Exercise Test | 9 | 2022 | 164 | 0.470 |
Why?
|
| Endothelial Cells | 5 | 2021 | 428 | 0.460 |
Why?
|
| Monitoring, Physiologic | 4 | 2012 | 268 | 0.460 |
Why?
|
| Phenotype | 7 | 2017 | 2378 | 0.460 |
Why?
|
| Atrioventricular Block | 1 | 2013 | 23 | 0.460 |
Why?
|
| Syncope | 1 | 2013 | 34 | 0.460 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 329 | 0.450 |
Why?
|
| Xanthenes | 1 | 2012 | 23 | 0.450 |
Why?
|
| Adenosine Triphosphate | 5 | 2022 | 314 | 0.450 |
Why?
|
| Glutamine | 1 | 2013 | 76 | 0.450 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2013 | 159 | 0.440 |
Why?
|
| Immunoblotting | 6 | 2015 | 268 | 0.440 |
Why?
|
| Protein Kinases | 3 | 2021 | 209 | 0.440 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2012 | 22 | 0.440 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2012 | 34 | 0.430 |
Why?
|
| Endarterectomy | 2 | 2011 | 20 | 0.420 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 179 | 0.420 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 353 | 0.420 |
Why?
|
| Romano-Ward Syndrome | 1 | 2011 | 1 | 0.420 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 166 | 0.410 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1464 | 0.410 |
Why?
|
| Mitosis | 1 | 2012 | 153 | 0.410 |
Why?
|
| Appetite Depressants | 4 | 1999 | 11 | 0.400 |
Why?
|
| Ventricular Remodeling | 4 | 2023 | 96 | 0.400 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 206 | 0.400 |
Why?
|
| Dexfenfluramine | 3 | 1999 | 4 | 0.400 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2010 | 4 | 0.390 |
Why?
|
| Registries | 4 | 2019 | 702 | 0.390 |
Why?
|
| Mice, Inbred BALB C | 4 | 2022 | 1047 | 0.390 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2010 | 32 | 0.390 |
Why?
|
| Cellular Senescence | 1 | 2011 | 94 | 0.390 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 138 | 0.390 |
Why?
|
| Pilot Projects | 4 | 2021 | 839 | 0.390 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1075 | 0.390 |
Why?
|
| Adult | 34 | 2020 | 25648 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 8 | 2020 | 3092 | 0.390 |
Why?
|
| Aged | 24 | 2024 | 18415 | 0.380 |
Why?
|
| NADPH Oxidases | 4 | 2021 | 81 | 0.380 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2008 | 214 | 0.370 |
Why?
|
| Phosphoric Diester Hydrolases | 3 | 2005 | 25 | 0.370 |
Why?
|
| Rotenone | 4 | 2023 | 17 | 0.370 |
Why?
|
| Cause of Death | 1 | 2011 | 277 | 0.370 |
Why?
|
| Ion Channel Gating | 7 | 2004 | 324 | 0.370 |
Why?
|
| Cardiology Service, Hospital | 1 | 2009 | 4 | 0.370 |
Why?
|
| Electron Transport | 5 | 2023 | 71 | 0.370 |
Why?
|
| Vascular Remodeling | 2 | 2020 | 21 | 0.360 |
Why?
|
| Mutation, Missense | 1 | 2011 | 276 | 0.360 |
Why?
|
| Simvastatin | 2 | 2007 | 106 | 0.360 |
Why?
|
| Fenfluramine | 3 | 1998 | 20 | 0.360 |
Why?
|
| Transcription Factors | 2 | 2018 | 1565 | 0.360 |
Why?
|
| Dietary Fats | 3 | 2004 | 135 | 0.360 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 43 | 0.350 |
Why?
|
| NADH Dehydrogenase | 2 | 2019 | 22 | 0.350 |
Why?
|
| Calcium Channel Blockers | 6 | 2007 | 203 | 0.350 |
Why?
|
| Electron Transport Complex I | 2 | 2020 | 28 | 0.350 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 58 | 0.350 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 3640 | 0.350 |
Why?
|
| PPAR alpha | 1 | 2008 | 10 | 0.340 |
Why?
|
| Antigens, CD | 1 | 2010 | 458 | 0.340 |
Why?
|
| Fibrosis | 3 | 2022 | 203 | 0.340 |
Why?
|
| Pyruvate Dehydrogenase Complex | 3 | 2017 | 13 | 0.340 |
Why?
|
| S Phase | 1 | 2008 | 62 | 0.330 |
Why?
|
| G1 Phase | 1 | 2008 | 63 | 0.330 |
Why?
|
| Gold Colloid | 1 | 2008 | 2 | 0.330 |
Why?
|
| Dimercaprol | 1 | 2008 | 6 | 0.330 |
Why?
|
| Tocopherols | 1 | 2008 | 6 | 0.330 |
Why?
|
| Silver | 1 | 2008 | 16 | 0.330 |
Why?
|
| Telomerase | 1 | 2008 | 55 | 0.330 |
Why?
|
| Prospective Studies | 10 | 2019 | 4213 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 458 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 104 | 0.320 |
Why?
|
| Coronary Disease | 3 | 1998 | 261 | 0.320 |
Why?
|
| Time Factors | 11 | 2018 | 5210 | 0.320 |
Why?
|
| Erectile Dysfunction | 3 | 2009 | 74 | 0.320 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 247 | 0.320 |
Why?
|
| Exercise | 1 | 2011 | 315 | 0.320 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 3 | 2004 | 15 | 0.320 |
Why?
|
| Rats, Inbred Strains | 13 | 2010 | 312 | 0.320 |
Why?
|
| Chelating Agents | 1 | 2008 | 69 | 0.320 |
Why?
|
| Bundle-Branch Block | 1 | 2008 | 48 | 0.310 |
Why?
|
| Nitric Oxide Synthase | 8 | 2003 | 125 | 0.310 |
Why?
|
| Polyamines | 2 | 1999 | 32 | 0.310 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2008 | 97 | 0.310 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 6 | 2014 | 7 | 0.310 |
Why?
|
| Pulmonary Alveoli | 4 | 2009 | 71 | 0.310 |
Why?
|
| Case-Control Studies | 6 | 2020 | 1805 | 0.310 |
Why?
|
| Predictive Value of Tests | 10 | 2020 | 1673 | 0.310 |
Why?
|
| Hemostasis | 3 | 2006 | 21 | 0.300 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 72 | 0.300 |
Why?
|
| Electrophysiology | 10 | 2008 | 401 | 0.300 |
Why?
|
| Mice, Knockout | 6 | 2021 | 1924 | 0.300 |
Why?
|
| Interleukin-6 | 2 | 2019 | 256 | 0.300 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.300 |
Why?
|
| Risk Factors | 11 | 2018 | 5417 | 0.300 |
Why?
|
| Energy Metabolism | 2 | 2022 | 271 | 0.290 |
Why?
|
| Calcium Signaling | 2 | 2007 | 129 | 0.290 |
Why?
|
| Referral and Consultation | 1 | 2009 | 328 | 0.290 |
Why?
|
| Cardiac Output | 5 | 2012 | 156 | 0.290 |
Why?
|
| Risk Assessment | 8 | 2018 | 2261 | 0.290 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2006 | 18 | 0.280 |
Why?
|
| Cytosol | 4 | 2017 | 189 | 0.280 |
Why?
|
| Pyrroles | 1 | 2007 | 184 | 0.280 |
Why?
|
| Perfusion | 11 | 2020 | 203 | 0.280 |
Why?
|
| Sirolimus | 1 | 2007 | 169 | 0.280 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 394 | 0.280 |
Why?
|
| Heart Rate | 2 | 2022 | 492 | 0.270 |
Why?
|
| Shab Potassium Channels | 6 | 2004 | 29 | 0.270 |
Why?
|
| Genetic Variation | 2 | 2018 | 1351 | 0.270 |
Why?
|
| Prognosis | 6 | 2020 | 3679 | 0.270 |
Why?
|
| Thromboembolism | 2 | 2018 | 119 | 0.270 |
Why?
|
| Cytokine Receptor gp130 | 2 | 2022 | 6 | 0.270 |
Why?
|
| NAD | 1 | 2005 | 65 | 0.270 |
Why?
|
| Arginine | 8 | 2004 | 136 | 0.270 |
Why?
|
| Disease Progression | 5 | 2015 | 1531 | 0.260 |
Why?
|
| Lung Injury | 3 | 2018 | 47 | 0.260 |
Why?
|
| Pulmonary Diffusing Capacity | 2 | 2018 | 24 | 0.260 |
Why?
|
| Systole | 3 | 2020 | 129 | 0.260 |
Why?
|
| Clitoris | 1 | 2004 | 4 | 0.260 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 1998 | 7 | 0.250 |
Why?
|
| Indians, North American | 1 | 2004 | 48 | 0.250 |
Why?
|
| Superoxides | 5 | 2020 | 73 | 0.250 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2005 | 32 | 0.250 |
Why?
|
| Mice, Nude | 2 | 2020 | 790 | 0.250 |
Why?
|
| Impotence, Vasculogenic | 1 | 2004 | 3 | 0.250 |
Why?
|
| Carbon Monoxide | 2 | 2018 | 90 | 0.250 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2015 | 134 | 0.240 |
Why?
|
| Biology | 2 | 2021 | 50 | 0.240 |
Why?
|
| Pandemics | 2 | 2020 | 740 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2007 | 378 | 0.240 |
Why?
|
| DNA, Intergenic | 1 | 2023 | 25 | 0.240 |
Why?
|
| A549 Cells | 2 | 2021 | 39 | 0.230 |
Why?
|
| Premature Birth | 2 | 2021 | 113 | 0.230 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2023 | 55 | 0.230 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2003 | 12 | 0.230 |
Why?
|
| Down-Regulation | 2 | 2017 | 504 | 0.230 |
Why?
|
| Electrons | 1 | 2023 | 49 | 0.230 |
Why?
|
| Biological Factors | 1 | 2003 | 18 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 879 | 0.230 |
Why?
|
| Lung Diseases | 2 | 2019 | 263 | 0.220 |
Why?
|
| Myocardial Infarction | 2 | 2024 | 376 | 0.220 |
Why?
|
| X-Ray Microtomography | 1 | 2023 | 80 | 0.220 |
Why?
|
| Heart | 5 | 2013 | 539 | 0.220 |
Why?
|
| Comorbidity | 3 | 2018 | 943 | 0.220 |
Why?
|
| Placental Circulation | 1 | 2002 | 10 | 0.220 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 532 | 0.220 |
Why?
|
| Mammary Arteries | 1 | 2003 | 31 | 0.220 |
Why?
|
| Oxidants | 2 | 2010 | 86 | 0.220 |
Why?
|
| Smoking | 2 | 2006 | 609 | 0.220 |
Why?
|
| Research | 3 | 2018 | 253 | 0.220 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 4 | 2007 | 4 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 3362 | 0.220 |
Why?
|
| NG-Nitroarginine Methyl Ester | 7 | 1999 | 45 | 0.220 |
Why?
|
| Methyltransferases | 1 | 2023 | 182 | 0.210 |
Why?
|
| Up-Regulation | 2 | 2017 | 712 | 0.210 |
Why?
|
| Herpes Simplex | 1 | 2023 | 202 | 0.210 |
Why?
|
| Diastole | 2 | 2020 | 144 | 0.210 |
Why?
|
| Pyruvate Kinase | 2 | 2022 | 13 | 0.210 |
Why?
|
| Acetylcholine | 6 | 2004 | 176 | 0.210 |
Why?
|
| Cohort Studies | 7 | 2020 | 2767 | 0.210 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2021 | 11 | 0.210 |
Why?
|
| Feeding Behavior | 1 | 2004 | 324 | 0.210 |
Why?
|
| Extracellular Matrix | 2 | 2022 | 232 | 0.210 |
Why?
|
| Renal Artery | 1 | 2002 | 64 | 0.210 |
Why?
|
| Adenoviridae | 6 | 2010 | 345 | 0.210 |
Why?
|
| Phagocytosis | 1 | 2021 | 85 | 0.200 |
Why?
|
| Drug Therapy, Combination | 5 | 2009 | 894 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2010 | 407 | 0.200 |
Why?
|
| Delayed Rectifier Potassium Channels | 4 | 2002 | 13 | 0.200 |
Why?
|
| Cytokines | 1 | 2005 | 776 | 0.200 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2022 | 77 | 0.200 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2021 | 100 | 0.200 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 244 | 0.200 |
Why?
|
| Proteolysis | 1 | 2021 | 100 | 0.190 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 4 | 2004 | 11 | 0.190 |
Why?
|
| Placenta | 1 | 2002 | 175 | 0.190 |
Why?
|
| Iron | 1 | 2021 | 164 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1621 | 0.190 |
Why?
|
| Enzyme Activation | 4 | 2012 | 692 | 0.190 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 187 | 0.190 |
Why?
|
| Infant, Premature | 1 | 2023 | 290 | 0.190 |
Why?
|
| Phosphorylation | 3 | 2021 | 1106 | 0.190 |
Why?
|
| Peptides | 5 | 2004 | 639 | 0.190 |
Why?
|
| Aorta | 3 | 2020 | 280 | 0.190 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 18 | 0.190 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2001 | 119 | 0.190 |
Why?
|
| Anticoagulants | 3 | 2011 | 408 | 0.190 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 1753 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2010 | 1961 | 0.190 |
Why?
|
| Random Allocation | 3 | 2020 | 332 | 0.190 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2020 | 371 | 0.180 |
Why?
|
| Animals, Newborn | 6 | 2013 | 510 | 0.180 |
Why?
|
| Endothelin-1 | 1 | 2000 | 41 | 0.180 |
Why?
|
| Survival Rate | 3 | 2020 | 1863 | 0.180 |
Why?
|
| Myocardial Stunning | 1 | 2020 | 12 | 0.180 |
Why?
|
| Body Temperature | 1 | 2020 | 124 | 0.180 |
Why?
|
| Sulfonamides | 2 | 2006 | 300 | 0.180 |
Why?
|
| Catheters | 1 | 2020 | 74 | 0.180 |
Why?
|
| Antioxidants | 5 | 2001 | 223 | 0.180 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2020 | 152 | 0.180 |
Why?
|
| Ion Channels | 2 | 1998 | 246 | 0.180 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 106 | 0.180 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1999 | 8 | 0.180 |
Why?
|
| Chlorides | 1 | 2020 | 103 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2018 | 104 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2023 | 7993 | 0.180 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 102 | 0.170 |
Why?
|
| Feasibility Studies | 1 | 2021 | 751 | 0.170 |
Why?
|
| Rats, Wistar | 2 | 2019 | 297 | 0.170 |
Why?
|
| Cell Line, Tumor | 4 | 2022 | 2426 | 0.170 |
Why?
|
| Outpatients | 1 | 2019 | 94 | 0.170 |
Why?
|
| Myocardial Contraction | 2 | 2012 | 244 | 0.170 |
Why?
|
| HLA-DP alpha-Chains | 1 | 2018 | 6 | 0.170 |
Why?
|
| Chemoreceptor Cells | 2 | 2002 | 65 | 0.170 |
Why?
|
| HLA-DP beta-Chains | 1 | 2018 | 8 | 0.170 |
Why?
|
| SOXF Transcription Factors | 1 | 2018 | 9 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 508 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2018 | 4 | 0.170 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2018 | 4 | 0.170 |
Why?
|
| Annexin A1 | 1 | 2018 | 5 | 0.170 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 350 | 0.170 |
Why?
|
| Mitral Valve Stenosis | 1 | 2018 | 37 | 0.170 |
Why?
|
| Dietary Sucrose | 1 | 1998 | 13 | 0.170 |
Why?
|
| Potassium | 6 | 2004 | 281 | 0.170 |
Why?
|
| Thrombospondins | 1 | 2018 | 14 | 0.170 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2018 | 12 | 0.170 |
Why?
|
| Fish Oils | 2 | 1989 | 11 | 0.170 |
Why?
|
| Phospholipids | 3 | 1992 | 111 | 0.170 |
Why?
|
| Free Radical Scavengers | 1 | 1998 | 59 | 0.160 |
Why?
|
| Aftercare | 1 | 2019 | 85 | 0.160 |
Why?
|
| Amino Acid Oxidoreductases | 2 | 1995 | 9 | 0.160 |
Why?
|
| DNA | 2 | 2023 | 1294 | 0.160 |
Why?
|
| Energy Intake | 1 | 1998 | 98 | 0.160 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 114 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1036 | 0.160 |
Why?
|
| Ion-Selective Electrodes | 1 | 1998 | 4 | 0.160 |
Why?
|
| Telangiectasis | 1 | 2018 | 6 | 0.160 |
Why?
|
| Anesthesia | 1 | 2020 | 164 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 592 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 1197 | 0.160 |
Why?
|
| Blood Flow Velocity | 1 | 2018 | 197 | 0.160 |
Why?
|
| Ontario | 1 | 2018 | 52 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1041 | 0.160 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 188 | 0.160 |
Why?
|
| Models, Cardiovascular | 2 | 1996 | 98 | 0.160 |
Why?
|
| Blood Platelets | 1 | 1998 | 149 | 0.160 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2017 | 14 | 0.160 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2017 | 19 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 1 | 2020 | 301 | 0.160 |
Why?
|
| Pregnancy | 9 | 2014 | 2894 | 0.160 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 1998 | 51 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2020 | 814 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 1998 | 165 | 0.160 |
Why?
|
| von Willebrand Diseases | 1 | 2017 | 6 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 163 | 0.160 |
Why?
|
| Sheep | 6 | 2008 | 239 | 0.160 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2017 | 30 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2018 | 173 | 0.150 |
Why?
|
| Age Distribution | 1 | 2018 | 204 | 0.150 |
Why?
|
| Prevalence | 3 | 2018 | 1239 | 0.150 |
Why?
|
| Classification | 1 | 2017 | 54 | 0.150 |
Why?
|
| Enzyme Induction | 2 | 2007 | 88 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2018 | 1538 | 0.150 |
Why?
|
| NFATC Transcription Factors | 2 | 2007 | 29 | 0.150 |
Why?
|
| Bradykinin | 4 | 2003 | 46 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 860 | 0.150 |
Why?
|
| Administration, Oral | 3 | 2003 | 684 | 0.150 |
Why?
|
| Aminorex | 1 | 1996 | 1 | 0.150 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 66 | 0.150 |
Why?
|
| Free Radicals | 7 | 1995 | 73 | 0.150 |
Why?
|
| Heart Atria | 1 | 2018 | 250 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 428 | 0.150 |
Why?
|
| Minnesota | 3 | 2018 | 46 | 0.150 |
Why?
|
| Bronchopulmonary Dysplasia | 2 | 2008 | 39 | 0.150 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2016 | 31 | 0.150 |
Why?
|
| Child, Preschool | 4 | 2018 | 3612 | 0.150 |
Why?
|
| Hernia, Diaphragmatic | 2 | 2011 | 10 | 0.150 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 3 | 2015 | 14 | 0.150 |
Why?
|
| Breath Tests | 1 | 1996 | 55 | 0.150 |
Why?
|
| Fishes | 1 | 1998 | 137 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 141 | 0.140 |
Why?
|
| Glyburide | 4 | 2001 | 32 | 0.140 |
Why?
|
| Diagnostic Imaging | 3 | 2015 | 469 | 0.140 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 1996 | 48 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 645 | 0.140 |
Why?
|
| Carbazoles | 1 | 1996 | 51 | 0.140 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1996 | 19 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 455 | 0.140 |
Why?
|
| Cardiovascular Agents | 3 | 2015 | 56 | 0.140 |
Why?
|
| Diuretics | 2 | 2009 | 124 | 0.140 |
Why?
|
| Gene Expression Regulation | 5 | 2020 | 1920 | 0.140 |
Why?
|
| Scorpion Venoms | 3 | 2004 | 25 | 0.140 |
Why?
|
| Muscle Tonus | 1 | 1995 | 19 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 547 | 0.140 |
Why?
|
| Quality of Life | 1 | 2004 | 1585 | 0.140 |
Why?
|
| Warfarin | 2 | 2009 | 103 | 0.140 |
Why?
|
| Dithionite | 1 | 1995 | 2 | 0.140 |
Why?
|
| NADPH Dehydrogenase | 1 | 1995 | 11 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2017 | 272 | 0.130 |
Why?
|
| Exercise Tolerance | 2 | 2013 | 48 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2004 | 1373 | 0.130 |
Why?
|
| Glomerular Mesangium | 1 | 1995 | 23 | 0.130 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1995 | 20 | 0.130 |
Why?
|
| Infant | 3 | 2018 | 3046 | 0.130 |
Why?
|
| Aconitate Hydratase | 1 | 2015 | 11 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 290 | 0.130 |
Why?
|
| Arteries | 4 | 2002 | 176 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2009 | 589 | 0.130 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2014 | 2 | 0.130 |
Why?
|
| CHO Cells | 3 | 2005 | 187 | 0.130 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2018 | 235 | 0.130 |
Why?
|
| Diet | 1 | 1998 | 443 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 318 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 456 | 0.130 |
Why?
|
| Creatinine | 2 | 2008 | 338 | 0.130 |
Why?
|
| Benzoates | 1 | 2014 | 44 | 0.130 |
Why?
|
| United States | 8 | 2021 | 6672 | 0.130 |
Why?
|
| Fetus | 5 | 1999 | 226 | 0.130 |
Why?
|
| Gene Targeting | 2 | 2007 | 72 | 0.130 |
Why?
|
| Indoles | 1 | 1996 | 318 | 0.120 |
Why?
|
| Electric Conductivity | 4 | 2002 | 144 | 0.120 |
Why?
|
| Cricetinae | 3 | 2005 | 560 | 0.120 |
Why?
|
| Incidence | 2 | 2018 | 1577 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 1996 | 150 | 0.120 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2014 | 67 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 125 | 0.120 |
Why?
|
| Adolescent | 4 | 2018 | 8981 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1208 | 0.120 |
Why?
|
| Sirtuin 3 | 1 | 2013 | 29 | 0.120 |
Why?
|
| rho-Associated Kinases | 2 | 2013 | 159 | 0.120 |
Why?
|
| Diazooxonorleucine | 1 | 2013 | 5 | 0.120 |
Why?
|
| Canada | 3 | 2009 | 204 | 0.120 |
Why?
|
| Varicose Veins | 1 | 1993 | 10 | 0.120 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 1 | 2013 | 4 | 0.120 |
Why?
|
| Charybdotoxin | 3 | 2000 | 8 | 0.120 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 16 | 0.120 |
Why?
|
| Calcineurin Inhibitors | 1 | 2013 | 54 | 0.110 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2013 | 41 | 0.110 |
Why?
|
| Antibodies, Antinuclear | 1 | 2013 | 83 | 0.110 |
Why?
|
| Peptide Fragments | 3 | 2020 | 460 | 0.110 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 23 | 0.110 |
Why?
|
| Physical Conditioning, Animal | 1 | 2012 | 19 | 0.110 |
Why?
|
| Cell Separation | 3 | 2003 | 196 | 0.110 |
Why?
|
| Fluoxetine | 2 | 2006 | 42 | 0.110 |
Why?
|
| Dobutamine | 1 | 2012 | 61 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 151 | 0.110 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 79 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 806 | 0.110 |
Why?
|
| Aorta, Abdominal | 1 | 1992 | 60 | 0.110 |
Why?
|
| Substance P | 3 | 1994 | 61 | 0.110 |
Why?
|
| Respiration | 4 | 2003 | 262 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 120 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2014 | 464 | 0.110 |
Why?
|
| Biomarkers | 5 | 2020 | 1718 | 0.110 |
Why?
|
| Ventricular Function, Left | 2 | 2011 | 592 | 0.110 |
Why?
|
| Cyclin B1 | 1 | 2012 | 17 | 0.110 |
Why?
|
| Cobalt | 1 | 2012 | 29 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 2271 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 582 | 0.110 |
Why?
|
| Transfection | 2 | 2012 | 896 | 0.110 |
Why?
|
| Diet Surveys | 2 | 2004 | 20 | 0.110 |
Why?
|
| Aortic Valve Stenosis | 1 | 1994 | 131 | 0.110 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 1135 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2012 | 87 | 0.110 |
Why?
|
| CDC2 Protein Kinase | 1 | 2012 | 45 | 0.110 |
Why?
|
| Aortic Valve | 1 | 1994 | 222 | 0.100 |
Why?
|
| Tacrolimus | 1 | 2013 | 373 | 0.100 |
Why?
|
| Genetic Vectors | 4 | 2006 | 439 | 0.100 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 63 | 0.100 |
Why?
|
| Ranolazine | 1 | 2011 | 4 | 0.100 |
Why?
|
| Trimetazidine | 1 | 2011 | 3 | 0.100 |
Why?
|
| Acetanilides | 1 | 2011 | 6 | 0.100 |
Why?
|
| Serine | 1 | 2012 | 99 | 0.100 |
Why?
|
| Young Adult | 3 | 2020 | 5976 | 0.100 |
Why?
|
| Hexokinase | 1 | 2011 | 19 | 0.100 |
Why?
|
| Models, Animal | 1 | 2013 | 263 | 0.100 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 20 | 0.100 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2002 | 40 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 2357 | 0.100 |
Why?
|
| Cytochrome c Group | 4 | 2001 | 82 | 0.100 |
Why?
|
| Rodentia | 1 | 2011 | 42 | 0.100 |
Why?
|
| Glycogen | 1 | 2011 | 59 | 0.100 |
Why?
|
| Environment | 1 | 2013 | 219 | 0.100 |
Why?
|
| World Health Organization | 1 | 2011 | 103 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2014 | 485 | 0.100 |
Why?
|
| Calcium Channels, L-Type | 2 | 2008 | 39 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2011 | 71 | 0.100 |
Why?
|
| Aging | 2 | 2010 | 691 | 0.100 |
Why?
|
| Dopamine | 1 | 2012 | 275 | 0.100 |
Why?
|
| Histones | 1 | 2013 | 311 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 273 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 67 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 235 | 0.100 |
Why?
|
| RNA Interference | 1 | 2012 | 369 | 0.100 |
Why?
|
| Tetraethylammonium | 3 | 2001 | 24 | 0.100 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1993 | 344 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 86 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 180 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 261 | 0.100 |
Why?
|
| Gene Expression | 4 | 2020 | 1284 | 0.100 |
Why?
|
| Vasomotor System | 2 | 1996 | 12 | 0.100 |
Why?
|
| Rats, Mutant Strains | 1 | 2010 | 23 | 0.090 |
Why?
|
| Shal Potassium Channels | 1 | 2010 | 5 | 0.090 |
Why?
|
| Inflammation | 1 | 2016 | 920 | 0.090 |
Why?
|
| Thermodilution | 1 | 2010 | 21 | 0.090 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2010 | 9 | 0.090 |
Why?
|
| Membrane Fusion | 1 | 2010 | 37 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 41 | 0.090 |
Why?
|
| Biomimetics | 1 | 2010 | 29 | 0.090 |
Why?
|
| Hypertension | 3 | 2000 | 1141 | 0.090 |
Why?
|
| Pyridines | 2 | 2009 | 310 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 115 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 2360 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 689 | 0.090 |
Why?
|
| Phthalimides | 1 | 2010 | 2 | 0.090 |
Why?
|
| Transduction, Genetic | 3 | 2006 | 153 | 0.090 |
Why?
|
| Alberta | 1 | 2009 | 8 | 0.090 |
Why?
|
| Time Management | 1 | 2009 | 9 | 0.090 |
Why?
|
| Porphyrins | 1 | 2010 | 39 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 16 | 0.090 |
Why?
|
| Culture Techniques | 2 | 2002 | 91 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2010 | 293 | 0.090 |
Why?
|
| Iloprost | 2 | 2006 | 15 | 0.090 |
Why?
|
| Mutation | 2 | 2020 | 3968 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2023 | 8489 | 0.090 |
Why?
|
| Hyperoxia | 2 | 2009 | 34 | 0.090 |
Why?
|
| Fundoplication | 1 | 2010 | 72 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6509 | 0.090 |
Why?
|
| Physical Exertion | 2 | 2000 | 39 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2013 | 673 | 0.090 |
Why?
|
| Metabolic Equivalent | 1 | 2009 | 1 | 0.090 |
Why?
|
| Species Specificity | 1 | 2011 | 678 | 0.090 |
Why?
|
| Specific Pathogen-Free Organisms | 4 | 1996 | 74 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 1999 | 88 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 66 | 0.090 |
Why?
|
| Physical Examination | 2 | 2014 | 149 | 0.090 |
Why?
|
| Child | 2 | 2018 | 6927 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 162 | 0.090 |
Why?
|
| Ankle | 1 | 2009 | 20 | 0.090 |
Why?
|
| Brachial Artery | 1 | 2009 | 36 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2010 | 172 | 0.090 |
Why?
|
| Phosphocreatine | 1 | 1989 | 14 | 0.090 |
Why?
|
| Guanidines | 1 | 1989 | 31 | 0.090 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2008 | 2 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2011 | 196 | 0.090 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2008 | 7 | 0.090 |
Why?
|
| Nifedipine | 2 | 2007 | 28 | 0.090 |
Why?
|
| E2F1 Transcription Factor | 1 | 2008 | 13 | 0.080 |
Why?
|
| Propionates | 1 | 1989 | 34 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1565 | 0.080 |
Why?
|
| Catheterization | 1 | 2010 | 232 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 62 | 0.080 |
Why?
|
| Mitogens | 1 | 2008 | 64 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2011 | 240 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2009 | 103 | 0.080 |
Why?
|
| Thrombolytic Therapy | 1 | 2011 | 220 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2009 | 90 | 0.080 |
Why?
|
| Coronary Vessels | 2 | 2020 | 177 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2005 | 33 | 0.080 |
Why?
|
| Homeostasis | 3 | 2024 | 409 | 0.080 |
Why?
|
| Oxidoreductases | 1 | 1989 | 112 | 0.080 |
Why?
|
| Waiting Lists | 1 | 2009 | 175 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 117 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2013 | 628 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 133 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 977 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 2903 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 243 | 0.080 |
Why?
|
| Gene Transfer Techniques | 3 | 2008 | 152 | 0.080 |
Why?
|
| Aerosols | 2 | 1999 | 44 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 859 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2008 | 1981 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2003 | 1019 | 0.080 |
Why?
|
| Mass Screening | 2 | 2009 | 618 | 0.080 |
Why?
|
| Thallium | 1 | 1987 | 8 | 0.080 |
Why?
|
| Pre-Excitation Syndromes | 1 | 1987 | 3 | 0.080 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2007 | 44 | 0.080 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2007 | 3 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2008 | 109 | 0.080 |
Why?
|
| Radioisotopes | 1 | 1987 | 45 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2008 | 128 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2010 | 695 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2009 | 280 | 0.070 |
Why?
|
| Rats, Nude | 1 | 2007 | 22 | 0.070 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 29 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2007 | 303 | 0.070 |
Why?
|
| Thionucleotides | 2 | 1999 | 56 | 0.070 |
Why?
|
| Prostaglandins, Synthetic | 1 | 2006 | 2 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2020 | 56 | 0.070 |
Why?
|
| Contrast Media | 1 | 2012 | 1078 | 0.070 |
Why?
|
| Pulmonary Heart Disease | 1 | 1986 | 4 | 0.070 |
Why?
|
| Xanthomatosis | 1 | 2006 | 5 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2007 | 83 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2010 | 1823 | 0.070 |
Why?
|
| Reference Values | 2 | 2010 | 674 | 0.070 |
Why?
|
| Thiophenes | 1 | 2006 | 48 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 126 | 0.070 |
Why?
|
| Isoxazoles | 1 | 2006 | 77 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 399 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2006 | 39 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2009 | 2501 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 268 | 0.070 |
Why?
|
| Homozygote | 1 | 2006 | 200 | 0.070 |
Why?
|
| Pergolide | 1 | 2005 | 3 | 0.070 |
Why?
|
| Administration, Inhalation | 2 | 2003 | 188 | 0.070 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2005 | 8 | 0.070 |
Why?
|
| Deferoxamine | 3 | 1989 | 18 | 0.070 |
Why?
|
| Glutathione | 2 | 2001 | 104 | 0.070 |
Why?
|
| Benzamides | 1 | 2006 | 229 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2705 | 0.070 |
Why?
|
| Nitrites | 2 | 1995 | 30 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 937 | 0.070 |
Why?
|
| Restaurants | 1 | 2004 | 5 | 0.060 |
Why?
|
| Wisconsin | 1 | 2004 | 39 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 162 | 0.060 |
Why?
|
| Respiration, Artificial | 3 | 2015 | 334 | 0.060 |
Why?
|
| Muscle Relaxation | 1 | 2004 | 18 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 1801 | 0.060 |
Why?
|
| Microdissection | 1 | 2004 | 18 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 1985 | 58 | 0.060 |
Why?
|
| Meclofenamic Acid | 2 | 1999 | 2 | 0.060 |
Why?
|
| Triterpenes | 1 | 2004 | 7 | 0.060 |
Why?
|
| Linear Models | 2 | 2012 | 421 | 0.060 |
Why?
|
| Lasers | 1 | 2004 | 106 | 0.060 |
Why?
|
| Ion Transport | 1 | 2004 | 81 | 0.060 |
Why?
|
| Myocardium | 2 | 2011 | 529 | 0.060 |
Why?
|
| Penile Erection | 1 | 2004 | 22 | 0.060 |
Why?
|
| Muscle Contraction | 2 | 1995 | 283 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 228 | 0.060 |
Why?
|
| Cholesterol | 1 | 2006 | 356 | 0.060 |
Why?
|
| Nucleocapsid | 1 | 2023 | 3 | 0.060 |
Why?
|
| Glucose Intolerance | 1 | 2004 | 96 | 0.060 |
Why?
|
| Health Education | 1 | 2004 | 101 | 0.060 |
Why?
|
| Organ Culture Techniques | 2 | 2019 | 135 | 0.060 |
Why?
|
| Nuclear Pore | 1 | 2023 | 11 | 0.060 |
Why?
|
| Societies, Medical | 3 | 2018 | 572 | 0.060 |
Why?
|
| Capsid | 1 | 2023 | 34 | 0.060 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2024 | 23 | 0.060 |
Why?
|
| Sincalide | 1 | 2003 | 1 | 0.060 |
Why?
|
| Panic | 1 | 2003 | 4 | 0.060 |
Why?
|
| Cholesterol, Dietary | 1 | 2003 | 27 | 0.060 |
Why?
|
| Dogs | 4 | 2000 | 685 | 0.060 |
Why?
|
| Culture Media | 2 | 1996 | 147 | 0.060 |
Why?
|
| Health Surveys | 1 | 2004 | 239 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2004 | 89 | 0.060 |
Why?
|
| Panic Disorder | 1 | 2003 | 22 | 0.060 |
Why?
|
| Food Preferences | 1 | 2003 | 26 | 0.060 |
Why?
|
| Time | 1 | 2003 | 77 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 429 | 0.060 |
Why?
|
| Taste | 1 | 2003 | 28 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2004 | 80 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2004 | 347 | 0.060 |
Why?
|
| omega-N-Methylarginine | 3 | 1992 | 17 | 0.060 |
Why?
|
| Digoxin | 1 | 2023 | 21 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 37 | 0.060 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2001 | 28 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2010 | 754 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 354 | 0.060 |
Why?
|
| Educational Status | 1 | 2003 | 188 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 999 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2003 | 79 | 0.050 |
Why?
|
| Uncoupling Agents | 1 | 2002 | 15 | 0.050 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2022 | 39 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 22 | 0.050 |
Why?
|
| Hypercapnia | 1 | 2002 | 43 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2022 | 46 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2022 | 23 | 0.050 |
Why?
|
| Liver | 2 | 2003 | 1230 | 0.050 |
Why?
|
| Prostaglandins F | 3 | 1986 | 12 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 557 | 0.050 |
Why?
|
| Myocardial Reperfusion | 2 | 1993 | 27 | 0.050 |
Why?
|
| Cell-Matrix Junctions | 1 | 2022 | 3 | 0.050 |
Why?
|
| Dinoprost | 3 | 1986 | 26 | 0.050 |
Why?
|
| Cell Line | 3 | 2020 | 2468 | 0.050 |
Why?
|
| Renal Circulation | 1 | 2002 | 61 | 0.050 |
Why?
|
| Catalase | 3 | 2001 | 48 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 865 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2015 | 60 | 0.050 |
Why?
|
| Actin-Related Protein 2-3 Complex | 1 | 2022 | 20 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 555 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2023 | 300 | 0.050 |
Why?
|
| Sulfur | 1 | 2021 | 28 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 41 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2022 | 154 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 212 | 0.050 |
Why?
|
| Headache | 1 | 2002 | 73 | 0.050 |
Why?
|
| Neomycin | 1 | 2001 | 7 | 0.050 |
Why?
|
| Oligopeptides | 2 | 2007 | 179 | 0.050 |
Why?
|
| Barium | 1 | 2001 | 31 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 21 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2601 | 0.050 |
Why?
|
| 5' Untranslated Regions | 1 | 2001 | 49 | 0.050 |
Why?
|
| 5,8,11,14-Eicosatetraynoic Acid | 1 | 2001 | 2 | 0.050 |
Why?
|
| Muscles | 1 | 2022 | 194 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2001 | 92 | 0.050 |
Why?
|
| Pulmonary Edema | 2 | 2005 | 50 | 0.050 |
Why?
|
| Prostaglandins | 1 | 2000 | 43 | 0.050 |
Why?
|
| Hexosamines | 1 | 2020 | 5 | 0.050 |
Why?
|
| Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) | 1 | 2020 | 4 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2022 | 270 | 0.050 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2020 | 11 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 1991 | 0.050 |
Why?
|
| Acylation | 1 | 2020 | 38 | 0.050 |
Why?
|
| Kidney | 2 | 2002 | 1241 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2001 | 256 | 0.050 |
Why?
|
| Diet, Fat-Restricted | 1 | 2000 | 30 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 208 | 0.050 |
Why?
|
| Phenylephrine | 2 | 2007 | 35 | 0.050 |
Why?
|
| Benzoquinones | 2 | 2001 | 27 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 64 | 0.050 |
Why?
|
| Metabolome | 1 | 2020 | 47 | 0.050 |
Why?
|
| Depression | 1 | 2004 | 473 | 0.050 |
Why?
|
| Ketanserin | 1 | 1999 | 10 | 0.050 |
Why?
|
| Luminol | 2 | 1989 | 2 | 0.050 |
Why?
|
| Tetraethylammonium Compounds | 2 | 1996 | 14 | 0.050 |
Why?
|
| Acridines | 2 | 1989 | 4 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2000 | 65 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 1999 | 12 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2020 | 74 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1621 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 1999 | 35 | 0.040 |
Why?
|
| American Heart Association | 2 | 2011 | 92 | 0.040 |
Why?
|
| NADPH Oxidase 2 | 1 | 1999 | 20 | 0.040 |
Why?
|
| Vitamin A | 1 | 1999 | 27 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2000 | 102 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2001 | 782 | 0.040 |
Why?
|
| Intracellular Membranes | 1 | 1999 | 117 | 0.040 |
Why?
|
| Phentermine | 1 | 1999 | 4 | 0.040 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 2 | 2008 | 13 | 0.040 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1999 | 11 | 0.040 |
Why?
|
| Cyclohexanols | 1 | 1999 | 7 | 0.040 |
Why?
|
| Guanosine Diphosphate | 1 | 1999 | 19 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 2 | 1996 | 25 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2022 | 447 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 1998 | 28 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2019 | 122 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2000 | 312 | 0.040 |
Why?
|
| Factor VII | 1 | 1998 | 2 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2013 | 729 | 0.040 |
Why?
|
| Factor VIII | 1 | 1998 | 7 | 0.040 |
Why?
|
| Methylene Blue | 2 | 1990 | 18 | 0.040 |
Why?
|
| Actins | 1 | 2022 | 451 | 0.040 |
Why?
|
| Metformin | 1 | 2000 | 128 | 0.040 |
Why?
|
| Rest | 1 | 1998 | 48 | 0.040 |
Why?
|
| Coronary Circulation | 3 | 2000 | 130 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 418 | 0.040 |
Why?
|
| Fibrinogen | 1 | 1998 | 56 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 1998 | 37 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 68 | 0.040 |
Why?
|
| Nitrogen Oxides | 1 | 1998 | 14 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2018 | 122 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 1998 | 129 | 0.040 |
Why?
|
| Photometry | 1 | 1998 | 14 | 0.040 |
Why?
|
| Hydrazines | 1 | 1998 | 30 | 0.040 |
Why?
|
| Nitroarginine | 2 | 2000 | 16 | 0.040 |
Why?
|
| Ozone | 1 | 1998 | 8 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1999 | 153 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 1998 | 72 | 0.040 |
Why?
|
| Calibration | 1 | 1998 | 99 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 193 | 0.040 |
Why?
|
| Ventilation-Perfusion Ratio | 2 | 2008 | 13 | 0.040 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2020 | 190 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2000 | 378 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 122 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 696 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 849 | 0.040 |
Why?
|
| Serotonin | 1 | 1998 | 218 | 0.040 |
Why?
|
| Fetal Hypoxia | 1 | 1997 | 13 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 1998 | 181 | 0.040 |
Why?
|
| Somatostatin | 1 | 1996 | 55 | 0.040 |
Why?
|
| Phenyl Ethers | 2 | 2011 | 13 | 0.040 |
Why?
|
| Aminoquinolines | 1 | 1996 | 17 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2018 | 248 | 0.040 |
Why?
|
| Equipment Design | 1 | 1998 | 406 | 0.040 |
Why?
|
| Alkaloids | 1 | 1996 | 45 | 0.040 |
Why?
|
| Gestational Age | 2 | 2008 | 311 | 0.040 |
Why?
|
| Labor, Obstetric | 1 | 1996 | 46 | 0.040 |
Why?
|
| Isoquinolines | 1 | 1996 | 72 | 0.040 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2015 | 7 | 0.030 |
Why?
|
| Diamide | 1 | 1995 | 3 | 0.030 |
Why?
|
| Ubiquinone | 1 | 1995 | 10 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 153 | 0.030 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 31 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 429 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1996 | 224 | 0.030 |
Why?
|
| Nitrates | 1 | 1995 | 35 | 0.030 |
Why?
|
| Phycoerythrin | 1 | 1995 | 2 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 256 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 1169 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 100 | 0.030 |
Why?
|
| Opioid Peptides | 1 | 1995 | 5 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 1995 | 21 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1996 | 223 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 1995 | 24 | 0.030 |
Why?
|
| Body Weight | 2 | 2011 | 459 | 0.030 |
Why?
|
| Ethers, Cyclic | 1 | 1994 | 7 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 1994 | 9 | 0.030 |
Why?
|
| Osmolar Concentration | 2 | 1992 | 181 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 96 | 0.030 |
Why?
|
| Onium Compounds | 1 | 1994 | 4 | 0.030 |
Why?
|
| Dithionitrobenzoic Acid | 3 | 2001 | 6 | 0.030 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1994 | 10 | 0.030 |
Why?
|
| Cattle | 1 | 1995 | 376 | 0.030 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1994 | 79 | 0.030 |
Why?
|
| Microelectrodes | 1 | 1994 | 81 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 1995 | 165 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 594 | 0.030 |
Why?
|
| Radionuclide Angiography | 1 | 1994 | 2 | 0.030 |
Why?
|
| Cyanides | 1 | 1993 | 16 | 0.030 |
Why?
|
| Antimycin A | 1 | 1993 | 13 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1456 | 0.030 |
Why?
|
| Acute Disease | 1 | 1996 | 826 | 0.030 |
Why?
|
| Immune System | 1 | 1995 | 93 | 0.030 |
Why?
|
| Hypertension, Portal | 1 | 2014 | 47 | 0.030 |
Why?
|
| Acetylation | 1 | 2013 | 121 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2014 | 80 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2015 | 175 | 0.030 |
Why?
|
| Thrombin | 1 | 1993 | 61 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 139 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 327 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2004 | 268 | 0.030 |
Why?
|
| Connective Tissue Diseases | 1 | 2014 | 67 | 0.030 |
Why?
|
| Calcimycin | 1 | 1992 | 33 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2015 | 2207 | 0.030 |
Why?
|
| Cell Death | 1 | 2013 | 256 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 1992 | 48 | 0.030 |
Why?
|
| Ferrous Compounds | 3 | 2001 | 17 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2013 | 498 | 0.030 |
Why?
|
| Autopsy | 1 | 2012 | 116 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1686 | 0.030 |
Why?
|
| Organ Size | 3 | 1999 | 364 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 756 | 0.030 |
Why?
|
| Iliac Vein | 1 | 2011 | 30 | 0.020 |
Why?
|
| Femoral Vein | 1 | 2011 | 35 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 364 | 0.020 |
Why?
|
| Heartburn | 1 | 2010 | 9 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2011 | 115 | 0.020 |
Why?
|
| Pyrrolizidine Alkaloids | 1 | 1990 | 1 | 0.020 |
Why?
|
| COS Cells | 1 | 2010 | 166 | 0.020 |
Why?
|
| Methods | 1 | 1989 | 152 | 0.020 |
Why?
|
| Hydroxylamines | 1 | 1989 | 7 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1540 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 1989 | 102 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 136 | 0.020 |
Why?
|
| Niacinamide | 1 | 2009 | 116 | 0.020 |
Why?
|
| Angiotensin II | 1 | 1989 | 94 | 0.020 |
Why?
|
| Exanthema | 1 | 2009 | 36 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 1989 | 118 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1989 | 167 | 0.020 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2009 | 19 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 114 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 54 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Liposomes | 1 | 1989 | 91 | 0.020 |
Why?
|
| Ischemia | 1 | 1990 | 243 | 0.020 |
Why?
|
| Diarrhea | 1 | 2009 | 182 | 0.020 |
Why?
|
| Serum Albumin | 1 | 1989 | 130 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 596 | 0.020 |
Why?
|
| Arachidonic Acid | 2 | 2001 | 63 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2009 | 435 | 0.020 |
Why?
|
| Mitochondrial Size | 1 | 2007 | 3 | 0.020 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1987 | 11 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2007 | 50 | 0.020 |
Why?
|
| Fetal Heart | 1 | 2007 | 13 | 0.020 |
Why?
|
| Chicago | 1 | 2012 | 1379 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 678 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1139 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2007 | 36 | 0.020 |
Why?
|
| Amides | 1 | 2007 | 60 | 0.020 |
Why?
|
| Atropine | 1 | 1986 | 59 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1987 | 220 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2007 | 62 | 0.020 |
Why?
|
| Glutathione Reductase | 1 | 1986 | 7 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 62 | 0.020 |
Why?
|
| Electron Transport Complex IV | 1 | 2006 | 47 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2007 | 234 | 0.020 |
Why?
|
| NADP | 1 | 1986 | 45 | 0.020 |
Why?
|
| Xanthine Oxidase | 1 | 1986 | 26 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 1986 | 49 | 0.020 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2007 | 72 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 1986 | 69 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2006 | 100 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 92 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2005 | 27 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 152 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2005 | 27 | 0.020 |
Why?
|
| Bepridil | 1 | 1985 | 1 | 0.020 |
Why?
|
| Nisoldipine | 1 | 1985 | 5 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1186 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 1985 | 37 | 0.020 |
Why?
|
| HIV Infections | 1 | 2014 | 772 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2005 | 117 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2006 | 187 | 0.020 |
Why?
|
| Angiography | 1 | 2005 | 208 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 379 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2006 | 387 | 0.020 |
Why?
|
| Pancreatic Elastase | 1 | 2004 | 15 | 0.020 |
Why?
|
| Training Support | 1 | 2004 | 23 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2006 | 912 | 0.020 |
Why?
|
| Food, Formulated | 1 | 2003 | 24 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 305 | 0.010 |
Why?
|
| Fasting | 1 | 2003 | 161 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 134 | 0.010 |
Why?
|
| Forecasting | 1 | 2004 | 304 | 0.010 |
Why?
|
| Schools, Medical | 1 | 2004 | 123 | 0.010 |
Why?
|
| Health Personnel | 1 | 2004 | 202 | 0.010 |
Why?
|
| Sulfhydryl Reagents | 1 | 2001 | 8 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2001 | 26 | 0.010 |
Why?
|
| Oleic Acid | 1 | 2001 | 14 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1830 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2216 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2001 | 281 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2000 | 67 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 162 | 0.010 |
Why?
|
| Herbicides | 1 | 1999 | 35 | 0.010 |
Why?
|
| Curriculum | 1 | 2004 | 539 | 0.010 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 1999 | 4 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2000 | 161 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1513 | 0.010 |
Why?
|
| Chloride Channels | 1 | 1997 | 42 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 1996 | 14 | 0.010 |
Why?
|
| Peptides, Cyclic | 1 | 1996 | 43 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1995 | 43 | 0.010 |
Why?
|
| Biotin | 1 | 1995 | 44 | 0.010 |
Why?
|
| Thymoma | 1 | 1995 | 30 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1995 | 131 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 316 | 0.010 |
Why?
|
| Disulfides | 1 | 1994 | 64 | 0.010 |
Why?
|
| Ferric Compounds | 1 | 1994 | 38 | 0.010 |
Why?
|
| Thrombin Time | 1 | 1993 | 4 | 0.010 |
Why?
|
| Hirudins | 1 | 1993 | 3 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 777 | 0.010 |
Why?
|
| Ligands | 1 | 1995 | 433 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1994 | 178 | 0.010 |
Why?
|
| Phospholipases | 1 | 1992 | 10 | 0.010 |
Why?
|
| Chromium | 1 | 1992 | 17 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1992 | 70 | 0.010 |
Why?
|
| Epinephrine | 1 | 1992 | 84 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1992 | 141 | 0.010 |
Why?
|
| Epithelium | 1 | 1992 | 319 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1014 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1995 | 408 | 0.010 |
Why?
|
| Cyanamide | 1 | 1989 | 1 | 0.010 |
Why?
|
| Hydroxylamine | 1 | 1989 | 5 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 1989 | 22 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 1988 | 202 | 0.000 |
Why?
|